GlassScriptPhysician profile
George B Cousin
NPI 1275532186
$10,998.42
in general payments reported to CMS, 2019-2025
49 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $1,139 · 2021: $1,237 · 2022: $1,706 · 2023: $1,745 · 2024: $1,611 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,012 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.39 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,460.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,279.32 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,032.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $759.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $715.08 | 2019-2024 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $539.83 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $434.99 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $427.95 | 2019-2025 | |
| Astellas Pharma US INC | $376.97 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.51 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $357.78 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $354.04 | 2021-2025 | |
| Allergan, INC. | $330.44 | 2019-2020 | |
| Corium, LLC | $309.92 | 2023-2025 | Azstarys |
| Esperion Therapeutics, INC. | $232.07 | 2020-2025 | Nexletol |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Cousin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.